Onconova Therapeutics, Inc. announced the appointment of Steven M. Fruchtman, M.D., as Chief Medical Officer and Senior Vice President, Research and Development. Dr. Fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes (MDS), hematologic malignancies and solid tumors. He will report to Thomas J. McKearn, M.D., Ph.D., the Company's President, Research and Development, and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates.

Dr. Fruchtman joins Onconova after a distinguished career in both academia and the industry. Most recently he was the Chief Medical Officer of Syndax Pharmaceuticals, where he led the clinical development of entinostat for breast cancer.